N@N

Auxilium Pharmaceuticals, Inc.: Auxilium Pharmaceuticals, Inc. Secures $30 Million Revolving Credit Line With Silicon Valley Ba

_{//business-finance.news-articles.net/content/200 .. evolving-credit-line-with-silicon-valley-ba.html}
^{Published in Business and Finance on Wednesday, August 5th 2009 at 3:30 GMT, Last Modified on 2009-08-05 03:30:33 by Market Wire}  

MALVERN, PA--(Marketwire - August 5, 2009) - Auxilium Pharmaceuticals, Inc. (NASDAQ: [ AUXL ]), a specialty biopharmaceutical company, today announced it has obtained a two-year revolving line of credit for working capital needs from Silicon Valley Bank (SVB) with $30 million committed at closing and an "accordion feature" that provides for an additional $10 million upon mutual agreement by the parties. The revolving line of credit may at times be subject to a borrowing base of trade accounts receivable and is secured by substantially all of the Company's assets, including intellectual property.

"This new credit facility provides additional financial flexibility at very attractive interest rates," said James E. Fickenscher, Chief Financial Officer of Auxilium Pharmaceuticals. "We believe this new partnership with Silicon Valley Bank should assist us in financing an anticipated inventory and receivables build as we prepare for and launch XIAFLEX in Dupuytren's contracture."

About Silicon Valley Bank

Silicon Valley Bank is the premier commercial bank for companies in the technology, life science, venture capital/private equity and premium wine industries. SVB provides a comprehensive suite of financing solutions, treasury management, corporate investment and international banking services to its clients worldwide. Through its focus on specialized markets and extensive knowledge of the people and business issues driving them, Silicon Valley Bank provides a level of service and partnership that measurably impacts its clients' success. Founded in 1983 and headquartered in Santa Clara, Calif., the company serves clients around the world through 27 U.S. offices and international operations in China, India, Israel and the United Kingdom. Silicon Valley Bank is a member of global financial services firm SVB Financial Group (NASDAQ: [ SIVB ]), with SVB Analytics, SVB Capital, SVB Global and SVB Private Client Services. More information on the company can be found at [ www.svb.com ].

Silicon Valley Bank is the California bank subsidiary and the commercial banking operation of SVB Financial Group. Banking services are provided by Silicon Valley Bank, a member of the FDIC and the Federal Reserve. SVB Financial Group is also a member of the Federal Reserve.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing to urologists, endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim® 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has five projects in clinical development. XIAFLEX™ (collagenase clostridium histolyticum), formerly referred to as AA4500, has completed phase III clinical trials for the treatment of Dupuytren's contracture, and the biologics license application is under review at the FDA for the treatment of Dupuytren's contracture. XIAFLEX is in phase IIb of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's transmucosal film product candidate for the treatment of overactive bladder (AA4010) and its fentanyl pain product using its transmucosal delivery system are in phase I of development. The Company is currently seeking a partner to further develop these transmucosal film product candidates. Auxilium has rights to additional pain products and products for hormone replacement and urologic disease using its transmucosal film delivery system. Auxilium also has options to all indications using XIAFLEX for non-topical formulations. For additional information, visit [ http://www.auxilium.com ].

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the commercialization of XIAFLEX, the effect of our new credit facility with SVB and our ability to finance our anticipated XIAFLEX inventory and receivables build; products in development for Peyronie's disease, Frozen Shoulder syndrome, overactive bladder, pain, hormone replacement and urologic disease; and all other statements containing projections, statements of future performance or expectations, or statements of plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). You can identify these statements by the fact that they use words such as "believe," "appears," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," and other words and terms of similar meaning in connection with any discussion of projections, future performance or expectations, plans or objectives for future operations (including statements of assumption underlying or relating to any of the foregoing). Actual results may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2008 under the heading "Risk Factors," which is on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at [ http://www.sec.gov ] or by means of Auxilium's home page on the Internet at [ http://www.Auxilium.com ] under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.

Auxilium disclaims responsibility for statements above in "About Silicon Valley Bank," which were provided by Silicon Valley Bank for inclusion in this release.